ライフサイエンスコーパス: live attenuated vaccine

1 VS::Deltawzy, was created and evaluated as a live attenuated vaccine.

2 culated for the inactivated vaccines and the live attenuated vaccine.

3 tivated vaccine as compared with those given live attenuated vaccine.

4 ed vaccine and 36% (95% CI, 0 to 59) for the live attenuated vaccine.

5 sting that the M2KO virus has potential as a live attenuated vaccine.

6 nts that can be used in the development of a live attenuated vaccine.

7 th -19% (95% CI, -113 to 33; P=0.55) for the live attenuated vaccine.

8 nd virulence to preclude its direct use as a live attenuated vaccine.

9 -2 may be a potential candidate for use as a live attenuated vaccine.

10 onse was of longer duration in recipients of live attenuated vaccine.

11 ping a safe and potentially more efficacious live attenuated vaccine.

12 l tropism of a virus is a new approach for a live attenuated vaccine.

13 entially serve as a positive-marker modified live-attenuated vaccine.

14 factors, and may differ for inactivated and live attenuated vaccines.

15 nother approach for prevention is the use of live attenuated vaccines.

16 irion inactivated vaccines and cold-adapted, live attenuated vaccines.

17 ied for development of classical swine fever live attenuated vaccines.

18 o understand virus biology and develop novel live attenuated vaccines.

19 had poor or diminished efficacy compared to live attenuated vaccines.

20 characteristics desirable in candidates for live attenuated vaccines.

21 derivatives of these pathogens may serve as live attenuated vaccines.

22 enesis and the design of a new generation of live attenuated vaccines.

23 n vivo and supports targeting the SH gene in live attenuated vaccines.

24 ations are good candidates for the design of live attenuated vaccines.

25 ored ILTV vaccines are less efficacious than live attenuated vaccines.

26 onally attenuate hMPV for the development of live attenuated vaccines.

27 man paramyxoviruses for rationally designing live attenuated vaccines.

28 gy, which combines the advantages of DNA and live attenuated vaccines.

29 s that can be mutated to generate successful live attenuated vaccines.

30 from that induced by live virus and possibly live attenuated vaccines.

31 ruses with vhs deleted have been proposed as live-attenuated vaccines.

32 quence identities (>/=98%) with the modified live-attenuated vaccines.

33 ty and activity is a strategy for generating live-attenuated vaccines.

34 ize may be more informative on the safety of live-attenuated vaccines.

35 option as safe, immunogenic, and protective live-attenuated vaccines.

36 cell culture has hindered the development of live-attenuated vaccines.

37 after receipt of dose 1 among recipients of live attenuated vaccine (3.8%) than among recipients of

38 We propose that this live attenuated vaccine acts like a silent natural infec

39 Immunization with live, attenuated vaccine (administered intranasally) is

40 s used to develop a two-component, trivalent live attenuated vaccine against human parainfluenza viru

41 defined F. novicida mutant (DeltaiglC) as a live attenuated vaccine against subsequent intranasal ch

42 related mainly to reduced protection of the live attenuated vaccine against type B viruses.

43 unique possibilities for developing improved live attenuated vaccines against arteriviruses and other

44 mid-deficient chlamydial strains function as live attenuated vaccines against genital and ocular infe

45 2 cytoplasmic tail mutants have potential as live attenuated vaccines against H5N1 influenza viruses.

46 the feasibility of using M2 tail mutants as live attenuated vaccines against H5N1 virus.

47 d and the polymerase could be used to design live attenuated vaccines against serious pathogens withi

48 on genetic engineering techniques--to design live attenuated vaccines against some of these viral age

49 gement provides a new approach to generating live attenuated vaccines against this class of virus.

50 At least 14 different live attenuated vaccines against this pathogen are avail

51 ChimeriVax-JE is a live, attenuated vaccine against Japanese encephalitis,

52 rtant implications for developing a modified live-attenuated vaccine against HEV.

53 ctious DNA clone as a genetically engineered live-attenuated vaccine against PCV2 infection and PMWS.

54 ications for development of both subunit and live-attenuated vaccines against ETEC and other enteric

55 ectors show significant promise as potential live-attenuated vaccines against human immunodeficiency

56 A similar approach may guide the design of live-attenuated vaccines against Lassa and other arenavi

57 The live attenuated vaccine also prevented influenza illness

58 The live attenuated vaccine also prevented influenza illness

59 However, live attenuated vaccines also induce strong CD8 T cell r

60 88(-/-) and Card9(-/-) mice immunized with a live, attenuated vaccine also fail to acquire protective

61 Among live attenuated vaccine and placebo recipients, cases we

62 placebo-controlled trial of inactivated and live attenuated vaccines and compared titers in subjects

63 egions display characteristics desirable for live attenuated vaccines and hold potential as vaccine c

64 r quality control of new lots of the current live-attenuated vaccine and provide insight for the rati

65 fe for mucosal application in humans, use of live-attenuated vaccines and microbial vectors, and prod

66 placebo-controlled trial of inactivated and live attenuated vaccines, and we evaluated the laborator

67 rts superseded by a final report, studies of live-attenuated vaccine, and studies of prepandemic seas

68 mmune responses similar to those elicited by live-attenuated vaccines, and its flexibility permits th

69 Live attenuated vaccines appear to be the most effective

70 vaccine appeared to be efficacious, whereas live attenuated vaccine appeared to be less so.

71 Our results suggest that the live attenuated vaccine approach should remain a viable

72 However, the live-attenuated vaccine approach faces formidable obstac

73 logous virus challenge and suggest that even live, attenuated vaccine approaches for AIDS will face s

74 Novel live attenuated vaccines are being developed that promis

75 Live attenuated vaccines are commonly used in the poultr

76 Live attenuated vaccines are considered the most viable

77 okines to enhance the safety and efficacy of live attenuated vaccines are discussed.

78 Live attenuated vaccines are more immunogenic and have t

79 Although live, attenuated vaccines are available to protect sever

80 ing and the potential to develop multivalent live-attenuated vaccines are discussed.

81 ion may serve as a novel approach to develop live attenuated vaccines as well as antiviral drugs for

82 The superior efficacy of live attenuated vaccine, as compared with inactivated va

83 tivity can lead to the development of novel, live attenuated vaccines, as well as antiviral drugs for

84 F) 17D vaccine is one of the most successful live attenuated vaccines available.

85 consideration should be taken when designing live attenuated vaccines based on deletions of nonstruct

86 new avenue for the development of arenavirus live attenuated vaccines based on rearrangement of their

87 al virulence factors, we hypothesized that a live-attenuated vaccine based on PA14 might elicit a bro

88 A single inoculation of the RVF MP-12 live attenuated vaccine by the aerosol or intranasal rou

89 Although live attenuated vaccines can provide potent protection a

90 oid of the p27 gene could be considered as a live attenuated vaccine candidate against visceral leish

91 cine is not available, and the more advanced live attenuated vaccine candidate in clinical trials req

92 P130 was then assessed for its efficacy as a live attenuated vaccine candidate in mice after challeng

93 human parainfluenza virus type 3 (PIV3) cp45 live attenuated vaccine candidate.

94 und that the immunogenicity in primates of a live-attenuated vaccine candidate for parainfluenza viru

95 Currently, the most promising live-attenuated vaccine candidate is a temperature-sensi

96 Here we report on a live-attenuated vaccine candidate that contains a 10-nuc

97 Unlike HEp-2 cells, in which wild-type and live-attenuated vaccine candidate viruses grow equally w

98 eltarelA DeltaspoT mutant may be a promising live-attenuated vaccine candidate.

99 enza viruses might have a great potential as live attenuated vaccine candidates against SIV infection

100 of gene rearrangement as a means to develop live attenuated vaccine candidates against Vesicular sto

101 rational development of safe and protective live attenuated vaccine candidates based on genome reorg

102 We have generated new influenza A virus live attenuated vaccine candidates by site-directed muta

103 ps but also will lead to the development new live attenuated vaccine candidates for hMPV.

104 can be assembled and have been developed as live attenuated vaccine candidates for several flaviviru

105 h potential for further development as novel live attenuated vaccine candidates that may rapidly cont

106 to safely attenuate FMDV and further develop live attenuated vaccine candidates to control such a fea

107 mmunogenicity, justifying their inclusion in live attenuated vaccine candidates to protect against th

108 t hosts, and this has motivated a search for live attenuated vaccine candidates.

109 could form the basis of a new generation of live attenuated vaccine candidates.

110 nymous but suboptimal substitutions provides live attenuated vaccine candidates.

111 bility of a CD-based approach for developing live-attenuated vaccine candidates against human-pathoge

112 We therefore generated 2 live-attenuated vaccine candidates based on the insertio

113 ost tissues, and identification of potential live-attenuated vaccine candidates.

114 The current live attenuated vaccines (chicken embryo origin [CEO] an

115 immunogenicity and protective efficacy of a live attenuated vaccine consisting of a recombinant seve

116 of mixed viral populations and indicate that live-attenuated vaccines containing virulent virus may b

117 eriVax-Japanese encephalitis (JE), the first live- attenuated vaccine developed with this technology

118 versus lower respiratory tract and bear upon live attenuated vaccine development.

119 lso boost the immunogenicity and efficacy of live attenuated vaccines directed against shigellosis, t

120 ach to the development of safe and effective live attenuated vaccines directed against VEEV and other

121 ach to the development of safe and effective live attenuated vaccines directed against VEEV and perha

122 esence of virulent revertant viruses in some live-attenuated vaccines, disease from vaccination is ra

123 Thus far, the goal of developing a safe, live attenuated vaccine effective after a single dose ha

124 Thus, multivalent live-attenuated vaccines elicit multifactorial protectiv

125 Isolation frequency was lowest among live attenuated vaccine failures, a reflection of lower

126 tive immune response and may have value as a live attenuated vaccine for aquaculture.

127 We previously reported that an experimental live attenuated vaccine for equine infectious anemia vir

128 to consideration when one is contemplating a live attenuated vaccine for HIV-1.

129 Development of a live attenuated vaccine for human NoV has not been possi

130 The absolute efficacies of the live attenuated vaccine for these end points were 8% (95

131 The recently licensed live attenuated vaccine for varicella-zoster virus is ef

132 oach for development of safe and efficacious live attenuated vaccines for AIDS.

133 serve as a novel target to rationally design live attenuated vaccines for aMPV and perhaps other para

134 rstanding may also enable the development of live attenuated vaccines for both RSV and other members

135 predicted to be safe, antibiotic-sensitive, live attenuated vaccines for cholera due to the O139 ser

136 The utility of live attenuated vaccines for controlling HIV epidemics i

137 for the development of safe and efficacious live attenuated vaccines for hMPV and other human paramy

138 serve as a novel target to rationally design live attenuated vaccines for hMPV and perhaps other para

139 a master donor strain for the generation of live attenuated vaccines for humans and livestock.

140 aches would add an HPV component to existing live attenuated vaccines for measles and typhoid fever.

141 s but also facilitate the development of new live attenuated vaccines for VSV, and perhaps other NNS

142 least a decade is required for approval of a live, attenuated vaccine for use in humans.

143 We developed an experimental live-attenuated vaccine for direct inoculation of the re

144 A live-attenuated vaccine for RVF, the MP-12 vaccine, is c

145 ovided an opportunity to design a successful live-attenuated vaccine for SARS-CoV and opens avenues f

146 Therefore, NU14 DeltawaaL is a candidate live-attenuated vaccine for the treatment and prevention

147 novel approach to produce safe and effective live-attenuated vaccines for DENV and other insect-borne

148 Two live-attenuated vaccines for gastroenteritis (Rotateq [M

149 unosuppression and aid in the development of live-attenuated vaccines for IBDV.

150 Among young children, live attenuated vaccine had significantly better efficac

151 Development of live, attenuated vaccines has traditionally relied on em

152 aluated in various animal lentivirus models, live attenuated vaccines have proven to be the most effe

153 Live, attenuated vaccines have prevented morbidity and m

154 Although live-attenuated vaccines have been safely administered t

155 However, the existing live-attenuated vaccines have the potential to revert to

156 RSV DeltaSH has been tested as a live attenuated vaccine in humans and cattle, and here w

157 eficient Chlamydia trachomatis to serve as a live attenuated vaccine in the genital tract.

158 h more serious adverse events than any other live attenuated vaccine in use today.

159 the protective immune mechanisms induced by live attenuated vaccines in primate models will be usefu

160 n eggs and has the potential to be used as a live-attenuated vaccine in humans.

161 s as a model to analyze characteristics of a live-attenuated vaccine in protection against virus-indu

162 Because concerns exist about the use of live-attenuated vaccines in immunocompromised individual

163 All eight live attenuated vaccines, including Japanese encephaliti

164 required to further define the nature of the live, attenuated vaccine-induced immunity against Coccid

165 V biology, including human host-pathogen and live, attenuated vaccine interactions; host and cell typ

166 ective vaccine than the previously developed live attenuated vaccine is needed for combating Francise

167 f adaptive immune response generated to this live attenuated vaccine is regulated by both the presenc

168 A live attenuated vaccine is the most promising vaccine st

169 /LASV reassortant (ML29) is a LASV candidate live-attenuated vaccine (LAV) that has shown promising r

170 ain Edmonston-Zagreb has long been used as a live-attenuated vaccine (LAV) to protect against measles

171 Implementation of live-attenuated vaccines (LAV) will represent a major st

172 Vaccination with live attenuated vaccines (LAVs) is an effective way for

173 Live-attenuated vaccines (LAVs) are the most advanced va

174 RSV live-attenuated vaccines (LAVs) have a history of safe t

175 Implementation of live-attenuated vaccines (LAVs) will represent a major s

176 challenge in a goat model as compared to the live attenuated vaccine MAP316F.

177 accines are ineffective or when the use of a live attenuated vaccine might be unsafe.

178 Successful live attenuated vaccines mimic natural exposure to patho

179 Boosting T cell-mediated immunity by live attenuated vaccine Mycobacterium bovis bacillus Cal

180 detected in mice immunized with the current live attenuated vaccine, Mycobacterium bovis-bacillus Ca

181 ess and safety concerns regarding the use of live attenuated vaccines or potent adjuvants in this pop

182 The multivalent live-attenuated vaccines overcame prior problems involvi

183 us, opening the possibility for its use as a live-attenuated vaccine platform for ZIKV and other clin

184 , we report the development of a recombinant live-attenuated vaccine platform strain that retains the

185 viral NS1 protein have emerged as promising live attenuated vaccine platforms.

186 As modified mRNA and live-attenuated vaccine platforms can restrict in utero

187 s a novel technology to sufficiently deliver live attenuated vaccine powders into the skin.

188 Live-attenuated vaccines present safety challenges, and

189 However, only the live, attenuated vaccine prevented immunosuppression-ind

190 Although a live-attenuated vaccine protects against MV, vaccination

191 nfluenza A (H3N2), 90% of placebo and 87% of live attenuated vaccine recipients but only 23% of inact

192 ive lymphocytes after immune activation with live attenuated vaccines remain poorly characterized.

193 In 1988, an inexpensive live-attenuated vaccine (SA14-14-2) was licensed in Chin

194 ion of the risks and benefits indicates that live attenuated vaccine should be a highly effective, sa

195 Finally, using the mutant as a live-attenuated vaccine showed significant promise for p

196 O-antigen polymerase) deletion mutant of Ft. live attenuated vaccine strain (Ft.LVS), designated Ft.L

197 udomallei Deltaasd mutant may be a promising live attenuated vaccine strain and a biosafe strain for

198 nscriptomic analysis of the M. gallisepticum live attenuated vaccine strain F and the virulent strain

199 A desirable trait in an effective live attenuated vaccine strain is an ability to persist

200 tularensis organisms were comparable to the live attenuated vaccine strain of Francisella tularensis

201 A candidate live attenuated vaccine strain was constructed for West

202 ve of SC602 (icsA iuc), a well-characterized live attenuated vaccine strain which has undergone sever

203 We used the live attenuated vaccine strain YFV-17D, which contains m

204 ens and livers than SL3261, the aroA mutant, live attenuated vaccine strain.

205 Whereas an F. tularensis live, attenuated vaccine strain (LVS) is the basis of an

206 th protection against plague, we developed a live-attenuated vaccine strain by deleting the Braun lip

207 tibility of the glycoprotein of the Candid#1 live-attenuated vaccine strain of JUNV in MACV replicati

208 sing reverse genetics, a set of experimental live attenuated vaccine strains based on recombinant H5N

209 throughout the poliovirus genome yielded the live attenuated vaccine strains of poliovirus.

210 Live attenuated vaccine strains of pseudorabies virus (P

211 Although live attenuated vaccine strains of simian immunodeficien

212 tive) strains of Salmonella may be useful as live attenuated vaccine strains or as vehicles for heter

213 Live attenuated vaccine strains, such as type I nonrepli

214 rae and a strong proinflammatory reaction to live attenuated vaccine strains.

215 on might be used to reduce reactogenicity of live attenuated vaccine strains.

216 aluating the neurovirulence potential of new live, attenuated vaccine strains and may also be of valu

217 coding engineered polymerases might serve as live, attenuated vaccine strains.

218 ge could be harnessed for the development of live-attenuated vaccine strains to combat HFAs.

219 lian host and warrant further development as live-attenuated vaccine strains.

220 A major safety concern of using live-attenuated vaccine strategies against AIDS is the p

221 Live attenuated vaccines such as SIV with a deleted nef

222 nfirmed influenza in the group that received live attenuated vaccine than in the group that received

223 dministration of dose 1 was more common with live attenuated vaccine than with inactivated vaccine, p

224 that might be deleted for the development of live attenuated vaccines that would be safer to use in s

225 e describe the first genetically engineered, live, attenuated vaccine that protects both BALB/c and C

226 sease has resulted in the development of two live, attenuated vaccines that are now licensed in many

227 We describe a live-attenuated vaccine that is safe and efficacious in

228 Thus, it might be possible to develop live-attenuated vaccines that are as immunogenic as pare

229 As a safe alternative to live attenuated vaccines, the immunogenicity and protect

230 Similar to a live attenuated vaccine, this approach should allow immu

231 e candidates demonstrate the potential for a live attenuated vaccine to protect against disease cause

232 veral Yersinia species have been utilized as live attenuated vaccines to prime protective immunity ag

233 n scavenging host iron and have been used in live-attenuated vaccines to combat plague epidemics.

234 Live-attenuated vaccines typically offer rapid and durab

235 ntigens expressed from multicopy plasmids in live attenuated vaccine vector strains of Vibrio cholera

236 ecombinant Sendai virus (rSeV) was used as a live, attenuated vaccine vector for intranasal inoculati

237 vivo expression of heterologous antigens by live, attenuated vaccine vector strains of Vibrio choler

238 Live attenuated vaccine vectors based on recombinant ves

239 Vaccination of mice with a live attenuated vaccine virus induces potent protection

240 Immunization with a live attenuated vaccine virus prior to challenge protect

241 e findings show that the immunogenicity of a live-attenuated vaccine virus in primates can be enhance

242 tally increase the level of attenuation of a live-attenuated vaccine virus.

243 redictive of restricted viral replication of live attenuated vaccine viruses in humans.

244 t remains unclear whether the replication of live attenuated vaccine viruses will be similarly enhanc

245 ic attenuation and host-range restriction of live attenuated vaccine viruses.

246 However, the live attenuated vaccine was found to be ineffective amon

247 fective (95% CI, 47 to 70; P<0.001), and the live attenuated vaccine was not observed to be effective

248 t the stalk and catalytic domains of NA as a live attenuated vaccine was shown to confer a strong IAV

249 The efficacy of the live attenuated vaccine was slightly less than that of t

250 he 2016-2017 A(H1N1)pdm09 strain used in the live attenuated vaccine was unchanged from 2015-2016, th

251 The live-attenuated vaccine was used to assess the impact of

252 The absolute efficacies of the live attenuated vaccine were 57% (95% CI, -3 to 82), 48%

253 ruses and human infections, new candidate H5 live attenuated vaccines were developed by using two dif

254 cination were higher among the recipients of live attenuated vaccine who were 6 to 11 months of age (

255 ent and control are under development, and a live attenuated vaccine with substantial potential for c

256 vaccine and 29% (95% CI, -14 to 55) for the live attenuated vaccine, with a relative efficacy of 60%

257 A single intranasal administration of live attenuated vaccine without adjuvant was sufficient

258 An effective live attenuated vaccine would be extremely useful in the